Other authors have demonstrated that sPD-L1 levels are significantly higher in melanoma patients compared to healthy individuals, especially in those with progressive disease [16] unlike our results, which showed no statistically significant differences between responders (RES) and non-responders (NRES). This evidence concerns the gene SPDL1 and melanoma.